Skip to main content

Table 3 Summary of results from studies reporting anti-HCV prevalence in MSM and prisoner

From: Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update

Author, year

Country

Recruiting period

Population as reported

Age, mean (SD)

Sample size

Anti-HCV prevalence (%) (95% CI)

Risk of selection bias

MSM

 Ireland, 2017 [39]

UK

28 February - 15 December 2014

MSM attending 4 genitourinary medicine clinics in Manchester

–

HIV+:735

HIV-:855

1.80 (−)

0.20 (−)

Low risk

 Vanhommerig, 2013 [40]

Netherland

2009–2012

HIV-infected MSM during 5 waves of anonymous surveys at Amsterdam STI clinic

–

439

7.10 (−)

High risk

 Cotte, 2018 [41]

France

January 2016 to May 2017

HIV+, HCV-negative MSM with serological follow-up in 2016

–

HIV+:13051

HIV-:930

5.10 (−)

1.80 (−)

Low risk

Prisoner

 Ekeke, 2018 [42]

UK

December 2015-February 2017

Prisoners entered Pentonville prison

–

1324

7.00 (−)

High risk

 Patel, 2016 [43]

UK

−

Inmates in a medium security prison

–

160

33.75 (−)

High risk

 Casella, 2016 [44]

Portugal

2014 and 2016

Inmates of 2 male prisons in the centre of Portugal (Pinheiro da Cruz and Setubal)

–

82

38.00 (−)

High risk

 Liberal, 2017 [45]

Portugal

January–April

Inmates from one of the largest prisons in Portugal

–

1208

15.70* (−)

High risk

 Svendsen, 2017 [46]

Norway

September 2015

At-risk populations in Trondheim, Norway

–

304

41.00 (−)

High risk

 Lerena, 2016 [47]

Spain

−

Inmates in a Northern region of Spain

(Cantabria) with 600 k inhabitants and focused on the regional long-stay prison of El Dueso

–

436

16.00 (−)

High risk